中医药在新冠肺炎治疗中的多模式参与。
Multimode participation of traditional Chinese medicine in the treatment of COVID-19.
作者信息
Dai Tieying, Zhang Leyin, Dai Xinyang, Zhang Xinran, Lu Beibei, Zheng Yuxi, Shen Deyi, Yan Yici, Ji Congqi, Yu Jieru, Sun Leitao
机构信息
Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Hangzhou, China.
Department of Oncology, Hangzhou TCM Hospital of Zhejiang Chinese Medical University (Hangzhou Hospital of Traditional Chinese Medicine), Hangzhou, China.
出版信息
Integr Med Res. 2021;10(Suppl):100781. doi: 10.1016/j.imr.2021.100781. Epub 2021 Oct 7.
BACKGROUND
The outbreak of COVID-19 has swiftly spread across China and all over the world, resulting in severe contagious pneumonia. However, no specific anti-COVID-19 drugs or methods are available for the treatment of this acute and fatal disease. In recent years, as the efficacy and safety of traditional Chinese medicine (TCM) have been universally acknowledged, it has been brought to a crucial status domestically and overseas for the treatment of COVID-19.
METHODS
We searched relevant literature, electronic databases, and official statements, diagnoses and protocols to retrieve studies and applications related to traditional Chinese medicine for COVID-19 in terms of regulations and policies, clinical evidence, preclinical rationale and big data analysis and then summarized the discovery and development of potential drugs and their targets.
RESULTS
Clinicians, researchers, governments, the public, colleges, institutes and companies collected and classified associated policies, regulations and actual contributions, searched clinical trials and preclinical experimental outcomes from databases, studied potential TCM drugs with possible mechanisms, retrieved numerous big data analysis method and gathered pooled results of compounds along with their effective targets to make traditional Chinese medicine vital to cover all stages of patients in the treatment and control of COVID-19.
CONCLUSION
Traditional Chinese medicine provides new evidence to support the clinical value of TCM for COVID-19.
背景
新型冠状病毒肺炎（COVID-19）疫情已迅速在中国乃至全球蔓延，导致严重的传染性肺炎。然而，目前尚无特效抗COVID-19药物或方法来治疗这种急性致命疾病。近年来，随着中医药疗效和安全性得到普遍认可，其在国内外治疗COVID-19方面被置于关键地位。
方法
我们检索了相关文献、电子数据库、官方声明、诊断方法和治疗方案，以获取与中医药治疗COVID-19相关的研究及应用，涉及法规政策、临床证据、临床前理论依据和大数据分析等方面，进而总结潜在药物及其靶点的发现与研发情况。
结果
临床医生、研究人员、政府、公众、高校、科研机构及企业收集并分类了相关政策、法规及实际贡献，从数据库中检索临床试验和临床前实验结果，研究具有可能作用机制的潜在中药药物，检索众多大数据分析方法，并汇总化合物及其有效靶点的综合结果，使得中医药在COVID-19的治疗与防控中对覆盖患者的各个阶段都至关重要。
结论
中医药为支持其对COVID-19的临床价值提供了新证据。
Zotero 插件